American Society of Hematology

Figure 5.

CD19-CARCD7− T cells outperform CD19-CARBulk in vivo. (A) Schematic of BV173 xenograft model: NSG mice were injected IV via tail vein with 3 × 103 BV173.ffluc cells on day 0 and a single dose of 3 × 106 T cells on day 7. (B) Bioluminescence data (total flux = photons per second) tumor only (N = 15), NT T cells (N = 5), CD19-CARBulk (N = 13), and CD19-CARCD7− (N = 13). (C) Survival curve (∗∗∗P < .001; ∗∗∗∗P < .0001, Mantel-Cox log-rank test). (D) Schematic of in vivo persistence experiment: NSG mice were injected with 3 × 103 BV173 cells 7 days prior to a single dose of 3 × 106 CAR.ffluc T cells. (E) Corresponding bioluminescence imaging. (F) Quantitative bioluminescence data. (G) Area under the curve (AUC) of total flux in photons per second of bioluminescence (N = 5 per group; P < .01 between NTCD7− and CD19-CARCD7−; all other comparisons, ns; 1-way ANOVA). ns, not significant.

CD19-CAR^CD7− T cells outperform CD19-CAR^Bulk in vivo. (A) Schematic of BV173 xenograft model: NSG mice were injected IV via tail vein with 3 × 10³ BV173.ffluc cells on day 0 and a single dose of 3 × 10⁶ T cells on day 7. (B) Bioluminescence data (total flux = photons per second) tumor only (N = 15), NT T cells (N = 5), CD19-CAR^Bulk (N = 13), and CD19-CAR^CD7− (N = 13). (C) Survival curve (∗∗∗P < .001; ∗∗∗∗P < .0001, Mantel-Cox log-rank test). (D) Schematic of in vivo persistence experiment: NSG mice were injected with 3 × 10³ BV173 cells 7 days prior to a single dose of 3 × 10⁶ CAR.ffluc T cells. (E) Corresponding bioluminescence imaging. (F) Quantitative bioluminescence data. (G) Area under the curve (AUC) of total flux in photons per second of bioluminescence (N = 5 per group; P < .01 between NT^CD7− and CD19-CAR^CD7−; all other comparisons, ns; 1-way ANOVA). ns, not significant.

This Feature Is Available To Subscribers Only